FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain
OKYO has more than doubled off its 52-week low of $0.902.
Summary
OKYO Pharma announced FDA authorization for a single-patient expanded access IND for urcosimod (0.05%) to treat severe neuropathic corneal pain, highlighting the drug's potential in an area with no approved therapies.
Key Events · Product Development and Regulatory · OKYO
-
FDA Authorizes Compassionate Use
The U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) application for urcosimod (0.05%).
-
Targets Neuropathic Corneal Pain
Urcosimod will be used in a patient with severe neuropathic corneal pain (NCP) who has limited therapeutic options and no FDA-approved treatments available.
-
Reinforces Development Pathway
This authorization follows urcosimod receiving the first IND to treat NCP and Fast Track designation, with a 120-patient Phase 2b/3 multiple-dose study expected to initiate this year.
Analysis · OKYO · Life Sciences
This FDA authorization for compassionate use, while for a single patient, is a positive regulatory development for OKYO Pharma's lead candidate, urcosimod. It underscores the significant unmet medical need in neuropathic corneal pain and provides an opportunity to gather additional real-world data for the drug. For a clinical-stage biopharmaceutical company, such authorizations can build confidence in the drug's profile and the company's commitment to addressing severe conditions, potentially supporting ongoing and future clinical development efforts.
At the time of this filing, OKYO was trading at $2.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.9M. The 52-week trading range was $0.90 to $3.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.